P1, N=34, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting

QGJY alleviates migraine and inhibits central sensitization in rats, potentially by downregulating P2X7R expression, concomitantly suppressing autophagy, attenuating microglial activation, and reducing pro-inflammatory cytokine release.

Intraoperatively, tumour manipulation precipitated abrupt hypertensive surges with bradycardia, necessitating nitroglycerine and sodium nitroprusside infusion. Intraoperative haemodynamic instability during adrenal manipulation should raise suspicion of catecholamine secretion, even in the absence of classical symptoms. The report emphasises the importance of invasive monitoring and anaesthetic preparedness to manage unexpected catecholamine release.

P2, N=10, Completed, University of Colorado, Denver | Recruiting --> Completed | N=20 --> 10 | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2026

Baizhi alleviates migraine through multi-target regulation of the gut-brain axis, including intestinal barrier repair, gut microbiota remodeling, and cerebral metabolic restoration. Notably, this study on Baizhi represents the first integration of spatial metabolomics (MALDI-MSI) with gut microbiome and systemic metabolomics to elucidate migraine mechanisms, providing a novel multi-omics strategy for understanding the holistic therapeutic effects of traditional Chinese medicine. These findings provide a mechanistic basis for its clinical application in migraine treatment.

P=N/A, N=68, Not yet recruiting, Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University | Phase classification: P4 --> P=N/A

P=N/A, N=100, Not yet recruiting, Tianjin Chest Hospital; Tianjin Chest Hospital

P=N/A, N=514, Not yet recruiting, Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai Hospital, Chinese Academy of Medical Sciences

P=N/A, N=1000, Not yet recruiting, Peking University First Hospital; Peking University First Hospital

P2, N=23, Completed, Baylor Research Institute | Unknown status --> Completed

This study provides cumulative evidence that caldesmon is a marker of age and inflammation-related changes in preglomerular vascular function. Our work supports the view that in the renal vasculature, caldesmon expression is age dependent and determines its sensitivity to the RhoA-associated protein kinase/p21-activated protein kinase 1 regulatory pathway.

P=N/A, N=60, Completed, Fayoum University Hospital